Author Archives: Molly Blauvelt

Two new therapies approved for the treatment of atopic dermatitis

We are pleased to announce that two new treatments have been recently approved by the FDA for the treatment of atopic dermatitis. Oregon Medical Research Center and our patients contributed to the approval by enrolling in the pivotal studies that provided the data showing the benefits of the treatment options. We want to thank all […]


Dr. Andrew Blauvelt named as one of the world’s most influential scientists

Each year the consulting and data analysis firm Clarivate compiles an annual list of researchers who have demonstrated significant and broad influence reflected in the publication of multiple papers frequently cited by their peers. The 2021 list includes about 3,800 researchers in 21 scientific fields, and another 2,800 researchers identified as having exceptional performance across several fields. […]


New treatment approved for mild-to-moderate atopic dermatitis

A new cream for the treatment of patients with mild-to-moderate atopic dermatitis (also commonly called eczema) was recently approved by the FDA. The generic name of the medication is ruxolitinib, and the trade name is Opzelura┬«. Typical treatments for eczema patients are dominated by topical steroids, such as triamcinolone cream, which patients will often use […]


The Psoriasis Pipeline

Recently, Dr. Andy Blauvelt, President of Oregon Medical Research Center (OMRC), was interviewed by the American Academy of Dermatology regarding upcoming drugs that will likely become available soon to treat psoriasis. Dr. Blauvelt, an international expert in psoriasis, has experience using all of these medications while participating in clinical trials for these drugs at OMRC. […]



Clinical Trial Evaluating New Eczema Drug Shows Promising Results

Atopic dermatitis (AD), also known as eczema, is a common skin disease that significantly impacts quality of life. One of the most distressing symptoms of this disease is itching, which can often lead to disruption of the skin barrier and skin infection. OMRC recently participated in a 16-week study evaluating a new treatment for AD, […]